Michael Okunewitch
Stock Analyst at Maxim Group
(0.63)
# 3,827
Out of 4,761 analysts
22
Total ratings
23.81%
Success rate
-12.41%
Average return
Main Sectors:
Stocks Rated by Michael Okunewitch
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CMMB Chemomab Therapeutics | Maintains: Buy | $4 → $7 | $1.71 | +309.36% | 2 | Feb 20, 2025 | |
| MYNZ Mainz Biomed | Initiates: Buy | $14 | $5.74 | +143.90% | 1 | Feb 14, 2025 | |
| LCTX Lineage Cell Therapeutics | Maintains: Buy | $5 → $3 | $0.68 | +343.79% | 1 | Jan 10, 2025 | |
| CTOR Citius Oncology | Initiates: Buy | $3 | $1.17 | +156.41% | 1 | Nov 27, 2024 | |
| OCGN Ocugen | Initiates: Buy | $4 | $0.68 | +488.24% | 1 | Oct 15, 2024 | |
| FBLG FibroBiologics | Initiates: Buy | $12 | $1.13 | +966.67% | 1 | Sep 24, 2024 | |
| LGVN Longeveron | Maintains: Buy | $15 → $6 | $1.56 | +284.62% | 2 | Aug 27, 2024 | |
| LEXX Lexaria Bioscience | Maintains: Buy | $3 → $12 | $1.45 | +727.59% | 2 | Mar 5, 2024 | |
| ACRV Acrivon Therapeutics | Initiates: Buy | $24 | $5.54 | +333.21% | 1 | Oct 5, 2023 | |
| ANEB Anebulo Pharmaceuticals | Initiates: Buy | $6 | $1.26 | +376.19% | 1 | Sep 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $108 → $18 | $3.47 | +418.73% | 3 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $225 | $0.96 | +23,396.24% | 1 | Apr 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $17.68 | +41.40% | 1 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $1.80 | +233.33% | 1 | Sep 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $4 | $0.39 | +925.64% | 1 | Mar 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $1.99 | +1,156.28% | 1 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $100 | $1.80 | +5,455.56% | 1 | Nov 30, 2021 |
Chemomab Therapeutics
Feb 20, 2025
Maintains: Buy
Price Target: $4 → $7
Current: $1.71
Upside: +309.36%
Mainz Biomed
Feb 14, 2025
Initiates: Buy
Price Target: $14
Current: $5.74
Upside: +143.90%
Lineage Cell Therapeutics
Jan 10, 2025
Maintains: Buy
Price Target: $5 → $3
Current: $0.68
Upside: +343.79%
Citius Oncology
Nov 27, 2024
Initiates: Buy
Price Target: $3
Current: $1.17
Upside: +156.41%
Ocugen
Oct 15, 2024
Initiates: Buy
Price Target: $4
Current: $0.68
Upside: +488.24%
FibroBiologics
Sep 24, 2024
Initiates: Buy
Price Target: $12
Current: $1.13
Upside: +966.67%
Longeveron
Aug 27, 2024
Maintains: Buy
Price Target: $15 → $6
Current: $1.56
Upside: +284.62%
Lexaria Bioscience
Mar 5, 2024
Maintains: Buy
Price Target: $3 → $12
Current: $1.45
Upside: +727.59%
Acrivon Therapeutics
Oct 5, 2023
Initiates: Buy
Price Target: $24
Current: $5.54
Upside: +333.21%
Anebulo Pharmaceuticals
Sep 21, 2023
Initiates: Buy
Price Target: $6
Current: $1.26
Upside: +376.19%
Aug 9, 2023
Maintains: Buy
Price Target: $108 → $18
Current: $3.47
Upside: +418.73%
Apr 12, 2023
Initiates: Buy
Price Target: $225
Current: $0.96
Upside: +23,396.24%
Dec 22, 2022
Initiates: Buy
Price Target: $25
Current: $17.68
Upside: +41.40%
Sep 28, 2022
Initiates: Buy
Price Target: $6
Current: $1.80
Upside: +233.33%
Mar 24, 2022
Initiates: Buy
Price Target: $4
Current: $0.39
Upside: +925.64%
Nov 30, 2021
Initiates: Buy
Price Target: $25
Current: $1.99
Upside: +1,156.28%
Nov 30, 2021
Initiates: Buy
Price Target: $100
Current: $1.80
Upside: +5,455.56%